Besifovir dipivoxil maleate: a novel antiviral agent with low toxicity and high genetic barriers for chronic hepatitis B.

Published in: Expert opinion on pharmacotherapy (2021)

BSV is a newly developed antiviral agent against HBV. This new agent has strong antiviral activity with low toxicity and a high barrier to resistance. Because there is concern that patients treated with a high dose of BSV require carnitine supplementation, BSV with carnitine supplementation is recommended during antiviral therapy.

Keyphrases

high dose
hepatitis b virus
oxidative stress
low dose
genome wide
stem cells
stem cell transplantation
mesenchymal stem cells
liver failure
bone marrow
copy number
cell therapy
liver fibrosis